Table 1.
Baseline characteristics
| Variable | SEARCH (Development) No. (%) | DPC (Validation) No. (%) |
|---|---|---|
| Total number of patients | 943 | 1792 |
| PSA nadir (ng/mL) | ||
| Undetectable | 642 (68) | 1709 (95) |
| 0.01 | 87 (9) | – |
| 0.02 | 67 (7) | – |
| 0.03 | 43 (4) | – |
| 0.04 | 25 (3) | – |
| 0.05–0.09 | 49 (5) | – |
| 0.10–0.19 | 31 (3) | 83 (5) |
| Age at surgery (years) | ||
| Mean (SD) | 60 (6.4) | 61 (7.3) |
| Median (IQR) | 60 (56–65) | 61 (56–66) |
| Veteran Affairs Medical Center | ||
| 1 | 320 (34) | – |
| 2 | 72 (8) | – |
| 3 | 237 (25) | – |
| 4 | 314 (33) | – |
| Race | ||
| White | 444 (48) | 1451 (81) |
| Non-white | 475 (52) | 337 (19) |
| Body mass index (kg/m2) | ||
| Mean (SD) | 28.0 (4.7) | 28.3 (5.5) |
| Median (IQR) | 27.7 (25.0–30.4) | 27.6 (25.5–30.4) |
| Biopsy Gleason score | ||
| 2–6 | 554 (61) | 1222 (73) |
| 3 + 4 | 215 (24) | 244 (14) |
| ≥4 + 3 | 137 (15) | 215 (13) |
| Preoperative stage: | ||
| T1 | 573 (64) | 1285 (80) |
| T2–T3 | 324 (36) | 329 (20) |
| Preoperative PSA (ng/mL) | ||
| Mean (SD) | 7.9 (7.5) | 6.7 (5.2) |
| Median (IQR) | 6.2 (4.5–9.0) | 5.5 (4.2–7.5) |
| Postoperative Gleason score | ||
| 2–6 | 360 (40) | 816 (46) |
| 3 + 4 | 389 (43) | 621 (35) |
| ≥4 + 3 | 159 (17) | 349 (19) |
| Extracapsular extension | 165 (18) | 434 (24) |
| Positive margins | 365 (40) | 564 (31) |
| Seminal vesicle invasion | 40 (4) | 108 (6) |
| Prostate weight (g) | ||
| Mean (SD) | 44 (24) | 44 (20) |
| Median (IQR) | 38 (31–51) | 40 (32–52) |
| Follow up (months) | ||
| Median (IQR) | 41 (21–65) | 45 (22–76) |
IQR, interquartile range; PSA, prostate-specific antigen; SD, standard deviation.